Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome

RASopathies are a class of developmental syndromes that result from congenital mutations in key elements of the RAS/RAF/MEK signaling pathway. A well-recognized RASopathy is the cardio-facio-cutaneous (CFC) syndrome characterized by a distinctive facial appearance, heart defects, and mental retardation. Clinically diagnosed CFC patients carry germ-line mutations in four different genes, B-RAF, MEK1, MEK2, and K-RAS. B-RAF is by far the most commonly mutated locus, displaying mutations that most often result in constitutive activation of the B-RAF kinase. Here, we describe a mouse model for CFC generated by germ-line expression of a B-RafLSLV600E allele. This targeted allele allows low levels of expression of B-RafV600E, a constitutively active B-Raf kinase first identified in human melanoma. B-Raf+/LSLV600E mice are viable and display several of the characteristic features observed in CFC patients, including reduced life span, small size, facial dysmorphism, cardiomegaly, and epileptic seizures. These mice also show up-regulation of specific catecholamines and cataracts, two features detected in a low percentage of CFC patients. In addition, B-Raf+/LSLV600E mice develop neuroendocrine tumors, a pathology not observed in CFC patients. These mice may provide a means of better understanding the pathophysiology of at least some of the clinical features present in CFC patients. Moreover, they may serve as a tool to evaluate the potential therapeutic efficacy of B-RAF inhibitors and establish the precise window at which they could be effective against this congenital syndrome.

[1]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[2]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[3]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[4]  X. Bustelo,et al.  The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. , 2009, The Journal of clinical investigation.

[5]  K. Rauen,et al.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.

[6]  J. Fagin,et al.  Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene , 2009, Proceedings of the National Academy of Sciences.

[7]  R. Marais,et al.  Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors , 2009, Human molecular genetics.

[8]  J. Reis-Filho,et al.  Oncogenic Braf induces melanocyte senescence and melanoma in mice. , 2009, Cancer cell.

[9]  M. Barbacid,et al.  A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. , 2008, The Journal of clinical investigation.

[10]  S. Ekvall,et al.  Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders , 2008, Journal of Medical Genetics.

[11]  Pablo Rodriguez-Viciana,et al.  Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. , 2008, Methods in enzymology.

[12]  J. Allanson,et al.  Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations , 2007, Journal of Medical Genetics.

[13]  G. Thomas,et al.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype , 2007, Nature Genetics.

[14]  K. Jones,et al.  Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio‐facio‐cutaneous syndrome from Costello syndrome , 2007, American journal of medical genetics. Part A.

[15]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[16]  R. Hennekam,et al.  Molecular and clinical characterization of cardio‐facio‐cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome , 2007, American journal of medical genetics. Part A.

[17]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[18]  X. Bustelo,et al.  Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. , 2007, Molecular biology of the cell.

[19]  J. Opitz,et al.  The cardiofaciocutaneous syndrome , 2006, Journal of Medical Genetics.

[20]  E. Álava,et al.  Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction , 2006, Nature Medicine.

[21]  Pablo Rodriguez-Viciana,et al.  Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.

[22]  R. Hennekam,et al.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.

[23]  C. Pritchard,et al.  Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. , 2005, Cancer research.

[24]  Yukichi Tanaka,et al.  Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.

[25]  M. Nilsson,et al.  Astrocyte activation and reactive gliosis , 2005, Glia.

[26]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[27]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[28]  K. Nathanson,et al.  Pheochromocytoma: the expanding genetic differential diagnosis. , 2003, Journal of the National Cancer Institute.

[29]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[30]  J. L. Stringer.  Repeated seizures increase GFAP and vimentin in the hippocampus , 1996, Brain Research.